216 results about "Human cell" patented technology

The invention discloses a humanized osteoporosis mouse model and a construction method thereof, and belongs to the technical field of biotechnology and animal models. The invention aims at the core defects of large species difference, insufficient humanization degree, low pathological simulation degree, unstable phenotype and the like of the existing osteoporosis model. The humanized osteoporosis mouse model is constructed through five core steps of experimental animal pretreatment, collagen-nano hydroxyapatite bionic scaffold preparation and cell pre-implantation, immune-bone metabolism double-derived system construction, progressive osteoporosis induction and model identification and verification. According to the method, double-person origination of immune and bone metabolism systems is realized for the first time, the colonization rate and survival time of human cells are greatly improved, the pathological process of clinical postmenopausal osteoporosis is accurately simulated, the phenotype of the model is stable and uniform, the reactivity matching degree with clinical drugs is high, and the method can be widely applied to research and development of anti-osteoporosis drugs and research of pathological mechanisms.

Disclosed in the present invention is an siRNA for inhibiting the expression of a urate transporter 1 (URAT1) gene in human cells. In the present invention, a plurality of siRNAs capable of inhibiting URAT1 expression are obtained by screening, and on this basis, appropriate modifications are performed to obtain sequences with improved target silencing ability. Drugs with the siRNAs as active ingredients are expected to be clinically applicable in the prevention and treatment of diseases related to the URAT1 target, such as gout, hyperuricemia, gouty arthritis and renal calculi.

The present disclosure provides methods of amplifying tissue samples derived from humans for purposes of treating certain diseases. The method comprises: isolating a small amount of associated tissue by biopsy or other tissue acquisition methods; the tissue is amplified in vitro, and meanwhile, natural functions are reserved; and re-implanting the amplified tissue to alleviate human disease. One example includes ex vivo expansion of human pancreatic islet tissue and reimplantation of the expanded cells into an individual with Type 1 diabetes for treatment and long term relief or cure of disease.

The present invention relates to recellularization of xenogeneic tissue. Specifically, the present invention relates to recellularization of xenogeneic tissue, which enables transplantation of non-immunogenic biological tissue with improved durability and regenerative capacity by generating xenogeneic tissue having regenerative capacity through human cell recellularization after removal of galactose-alpha-1,3-galactose (α-Gal) xenoantigens and non-galactose (non-Gal) xenoantigens.

The present invention provides a human T cell lacking human leukocyte antigen (HLA) class I molecule and containing an exogenous ST6GALNAC6 gene, which has the following characteristics (a) and / or (b):(a) CD62L-positive and CD45RA-positive(b) a total ATP production rate of a human T cell-containing cell population of 400 pmol / min / 105 cells or more and a mitochondrial spare respiratory capacity of 40 pmol / min / 105 cells or more, 5-6 days after the application of T cell proliferation stimulation to the cell population. According to the present invention, a low-immunogenic human T cell that can remain stably in the body for a long period of time after transplantation is provided, and the development of a versatile CAR-T cell or TCR-T cell for allotransplantation becomes possible by using the human T cell.

Systems and methods for highly-effective CRISPR-Cas based genomic editing within human chromosome 15q11-q13 have been developed as therapeutic interventions for Angelman Syndrome (AS). Selective single guide RNA molecules (sgRNAs) that impart enhanced CRISPR-Cas editing of genomic mutations associated with Angelman Syndrome in human cells are described. The engineered sgRNAs induce activity of non-pathogenic, paternal UBE3A alleles to reduce, reverse and / or prevent the causative neurodevelopmental defects of AS in a subject in need thereof. Compositions and methods of engineered crRNAs, sgRNAs thereof and ribonucleoprotein (RNP) complexes thereof are provided for enhanced genomic engineering with increased on-off target specificity and on-target editing efficacy for treatment of AS.

The present invention is a precursor crRNA for a type I CRISPR-Cas system having a modified nucleotide, in which at least one nucleotide is a modified nucleotide in a region comprising the 5'arm region of a first repeat sequence, the 5 '-side stem formation region of the first repeat sequence, and the ring formation region of the first repeat sequence.

Provided herein, inter alia, are compositions for treating Human T-cell lymphotropic virus type 1 (HTLV-1) associated diseases. The compositions include a protein having a zinc finger domain capable of binding a sequence within an HTLV-1 long terminal repeat (LTR). Further provided are methods of treating HTLV-1 associated diseases in a subject in need thereof. The methods include administering to the subject the protein including the zinc finger domain, or a nucleic acid encoding the protein.

A composition is provided comprising a cell population and pharmaceuticals derived from human gingival fibroblasts, present in proportions not found in natural gingival tissue, but having a cellular phenotype preferentially selected to express proteins favorable for angiogenesis and anti-inflammatory effects, while reducing the formation of cell populations that promote tumorigenesis and / or metalloproteinases that inhibit tissue regeneration. A method for producing such a composition that increases proliferation several times over compared to previously known methods is provided, and a method for using such a composition in a wide range of human cell therapies is also provided.

The invention relates to a novel human immunodeficiency virus envelope protein antigen expressed by mammals. Various embodiments of the invention relate to a polypeptide comprising 1-10 epitopes or more of the HIV envelope protein and a fusion protein, wherein the polypeptide lacks a transmembrane domain of the HIV gp41 protein. Such polypeptides can be expressed in mammalian cells, such as human cells, to produce polypeptides useful, for example, in the development of novel anti-HIV antibodies. The polypeptides described herein and the novel antibodies developed therefrom are generally useful in medical diagnostics, and they can also be used in the prophylactic and therapeutic treatment of HIV.

An assay for autologous primary immune cells is described, in which individual blood cells can be functionally screened simultaneously for individual antigens of interest, such as T-cell epitopes, without the need for HLA haplotype-specific reagents. An oligonucleotide-labeled hash-tracking system, followed by deconvolution via single-cell sequencing, correlates antigen reactivity with individual T cells.

To provide a gene modified cell including a modified T cell receptor (TCR) alpha steady region gene in a genome of the gene modified cell.SOLUTION: There is provided a gene modified cell including in a genome thereof, a modified human T cell receptor (TCR) alpha steady region gene, the modified human TCR alpha steady region gene includes, from 5' to 3', a 5' region of the human TCR alpha steady region gene, an exogenous polynucleotide, and a 3' region of the human TCR alpha steady region gene. The modified human TCR alpha steady region gene is a gene modified human T cell or a gene modified cell derived from a human T cell, and in comparison with a non-modified control cell, expression of an endogenous TCR on a cell surface is suppressed.SELECTED DRAWING: Figure 1

We have discovered that allogeneic HSC-engineered human iNKT (3rdHSC-iNKT) cells display potent anti-GvHD functions, by eliminating antigen-presenting myeloid cells in vitro and in xenograft models, without negatively impacting tumor eradication by allogeneic T cells in preclinical models of lymphoma and leukemia. The 3rdHSC-iNKT cells closely resembled the CD4−CD8− / + subsets of endogenous human iNKT cells in phenotype and functionality. Embodiments of the invention harness these discoveries in new methods and materials for alleviating graft versus host disease.

This document discloses compositions for use with engineered human cells, the compositions comprising a cell regulator or a carrier encoding a cell regulator. This document describes compositions comprising engineered cells, wherein the engineered cells are engineered human cells and contain modifications that make the engineered cells more resistant to alkylating drugs or nucleoside analogs compared to non-engineered human cells. Various methods for treating diseases are provided, including methods for treating cancer in a subject by administering cell regulators and / or engineered cells as therapeutic agents.

The invention belongs to the technical field of health drinks, and particularly relates to an agilawood capsule and a preparation method thereof. The agilawood leaf capsule overcomes the defect of insufficient absorption of effective components in a traditional agilawood leaf tea brewing and drinking mode, the agilawood leaves are reasonably treated and prepared into capsule dosage forms, so that a user can more conveniently, stably and efficiently take in the effective components in the agilawood leaves, and the effects of resisting oxidation, reducing blood sugar and blood fat, relieving constipation and the like of the agilawood leaf capsule are fully exerted. The adamantane-modified pullulan can be more easily taken and absorbed by human cells, and when the adamantane-modified pullulan is prepared into a capsule shell, the physiological activity of effective components in the agilawood leaf tea powder can be better exerted, and the absorption efficiency is improved.

The present application relates to the field of cosmetic technology, and more particularly to a full-link whitening and freckle-removing liposome and a preparation method thereof, the liposome comprising the following components: an aqueous phase, a membrane material and an oil phase. In the preparation process, 4-butyl resorcinol, nonapeptide-1, acetylchitosamine and ascorbic acid tetraisopalmitate are combined to form a full-link effect of signal inhibition-synthesis blockage-blocked conversion-metabolic acceleration, and a multi-target whitening and freckle-removing system is constructed. In addition, tranexamic acid, hydrolyzed yeast protein and schizophyllan are combined to synergistically make the finished product have excellent soothing and moisturizing effects. Furthermore, the finished product is prepared into a liposome capable of encapsulating active ingredients, which effectively improves the stability of the active ingredients, prevents their oxidation and inactivation, and the liposome structure is highly similar to the human cell membrane, is easy to penetrate the keratin layer gap, realizes targeted delivery to the deep layer of the epidermis, and makes the active ingredients truly act on the required site.

Provided are methods for treating pancreatic cancer with an antibody that specifically binds to human Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4).

The present disclosure relates to methods of producing engineered human cells. Methods may comprise providing a composition for inducing a modification of a target endogenous nucleic acid sequence in a nucleus of a human cell, wherein the composition comprises an amount of a Cas9 protein and an amount of a sgRNA in an in vitro environment free of the human cell. In some embodiments, the amount of sgRNA and the amount of Cas9 protein may be present in the composition at a weight ratio of 4:9 to 4:3. A Cas9 / sgRNA complex may form in the in vitro environment prior to being introduced into the human cell. Methods may further comprise introducing the Cas9 / sgRNA complex into the human cell via electroporation, wherein the Cas9 / sgRNA complex induces the modification of the target endogenous nucleic acid sequence in the nucleus of the human cell.

The present invention relates to a phage-based gene delivery system targeting human cells or animal cells, including immune cells, other human cells and cancer cells. In particular, the present invention relates to novel phage particles and associated phagemid expression systems and their production for the delivery of transgenes, comprising DNA encoding pathogen antigens, to human immune cells, suitable for use in vaccines and vaccine development against infectious diseases and cancers.

Non-human animals (and / or non-human cells) and methods of using and making the same are provided, which non-human animals (and / or non-human cells) have a genome comprising human antibody-encoding sequences (i.e., immunoglobulin genes). Non-human animals described herein express antibodies that contain human Igλ light chains, in whole or in part. In particular, non-human animals provided herein are, in some embodiments, characterized by expression of antibodies that contain human Igλ light chains, in whole or in part, that are encoded by human Ig light chain-encoding sequences inserted into an endogenous Igλ light chain locus of said non-human animals. Methods for producing antibodies from non-human animals are also provided.

Provided is a structure composed of a cell population comprising endothelial cells, astrocytes and pericytes, and a 3D (three dimensional) cell growth material within which the cell population is located. The structure has a TEER value of at least 450 Ω / cm2. The cells of the structure may be derived from the brain. The cells may be human cells, and in particular may be primary derived non-immortalised cells. The structure is particularly suited for use in a model of the blood brain barrier, and the invention also provides such a model. The structure is located in a container, in which it separates a first chamber located on a first side of the structure and a second chamber located on a second side of the structure. The first and second chambers respectively contain first and second liquids in contact with first and second sides of the structure. The liquids mimic the brain extracellular fluid and the blood. The blood brain barrier model provided may be used in models of brain disease, and to investigate uptake of agents into the brain or diseased brain.

This provides an unlimited supply method for human β-cells from stem cells. [Solution] Compositions and methods for promoting the differentiation of stem cells into beta cells using one or more epigenetically modified compounds are disclosed herein. The disclosure also relates to compositions and methods for selecting and enriching differentiated beta cells. The disclosure also relates to compositions and methods for irradiating a cell population to reduce proliferation. In some embodiments, methods are provided herein, comprising the step of contacting a population of pancreatic progenitor cells or their precursors with an epigenetically modified compound, wherein the contact step results in a population of endocrine cells in which the proportion of chromogranin A-positive (CHGA+) cells or C-peptide-positive and NKX6.1-positive (C-PEP+, NKX6.1+) cells is increased compared to a corresponding population of endocrine cells that have not been contacted with the epigenetically modified compound.

This invention relates to the field of biosensing technology, providing a self-driven sorting device with a near-field direct-write gradient grid and its fabrication method. The invention aims to solve the problems of existing microfluidic sorting devices, such as reliance on external power, susceptibility to stacking and clogging, and severe human background interference. The device constructs a spatially heterogeneous geometric topological grid in situ on a porous substrate using a near-field direct-write process, forming a three-level gradient path consisting of a primary coarse filtration zone, a secondary sorting zone, and a tertiary retention zone. This invention utilizes substrate capillary forces to drive sample flow and achieves physical guidance and precise retention of human cells through a deterministic lateral displacement mechanism. While significantly increasing sample processing throughput, it drastically reduces the proportion of human reads in sequencing, providing a convenient and efficient technical platform for automated preprocessing of complex biological samples and high-sensitivity clinical detection.

The invention relates to the technical field of human body dietary nutrient dietary fibers. The average molecular weight of the apple gum is 50,000-250,000 Daltons, the average molecular weight of the apple gum can reach 160-50,000 Daltons after being subjected to low molecularization, the apple gum acts in human cells and can prevent toxic cation poisoning, and main methods for preparing oligosaccharide from pectin at present are divided into a physical method, a chemical method and a biological enzyme method. The method comprises the following steps: 1, processing apple peel residues into powder; the method comprises the following steps: heating and drying apple pomace, continuously taking 20-50% of the pomace, mixing the pomace with undried apple juice to 100% by weight, then drying by using a dryer, and repeating the processes of drying and mixing the pomace. And 2, carrying out secondary heating. And heating the powdered apple fibers at 120 DEG C for 30 minutes. And 3, spray drying. The powder is sprayed and dried at a certain rate through a spray dryer according to a ratio of about 3: 1 to about 2: 1, so that microstructures such as powder smell, color, roughness and the like are improved.

The invention provides an application of SX-682 in preparation of a drug for resisting staphylococcus aureus infection, and the SX-682 has a CAS number of 1648843-04-2. According to the technical scheme, the novel medical application of the SX-682 is disclosed, and the SX-682 has better antibacterial activity on staphylococcus aureus and can inhibit formation of biofilms including methicillin-sensitive staphylococcus aureus (MSSA) and methicillin-resistant staphylococcus aureus (MRSA). The SX-682 has no significant toxicity to human cytotoxicity in the bacteriostatic concentration range, and provides key support for subsequent anti-infection application of the SX-682.

This invention belongs to the field of biomedicine and relates to a method for preparing a Kabuki syndrome brain organoid model and its application. This invention provides the application of GSK-3 inhibitors in the preparation of drugs for treating Kabuki syndrome. Currently existing Kabuki models include heterozygous mice, zebrafish, and 2D human cell models. However, the complexity of human brain development cannot be compared to animal models or single 2D cell models. In this invention, the inventors used CRISPR-CAS9 gene editing technology to knock out KMT2D and established a Kabuki syndrome brain organoid model using brain organoid technology. Studies have found that, compared to the wild type, the Kabuki syndrome brain organoid exhibits premature differentiation of excessive GABAergic neurons. Furthermore, by testing the dosage and time window of the small molecule chir99021, we found that this small molecule can restore the phenotype of abnormal neuronal differentiation in the Kabuki syndrome brain organoid. This discovery will provide new insights for the treatment of Kabuki syndrome.

The invention relates to application of DNA polymerase in long-fragment precise gene editing and construction in a plurality of human-derived cell lines. The invention belongs to the technical field of biological medicine. A novel gene editing system MMEJ-Pol theta is created by applying DNA polymerase Pol theta and a key functional structure domain, the accuracy, safety and editing efficiency of long-fragment gene editing in a eukaryotic genome are remarkably improved through a micro homologous end linking method, and an effective tool is provided for transformation application of the gene editing system in gene therapy and cell therapy.

The invention discloses a human expression optimized Nipah virus N gene and application thereof in preparation of Nipah pseudovirus, belongs to the technical field of biology, and constructs a segment of Nipah virus N gene sequence optimized by human cell expression codons and constructs a recombinant vector pcDNA3.1-NiV-N-opti. The recombinant vector pcDNA3.1-NiV-N-opti is used as a pseudovirus expression vector, the recombinant vector pcDNA3.1-NiV-N-opti and pseudovirus packaging plasmids are used for preparing the kit for the nipah pseudovirus, the nipah pseudovirus can be efficiently obtained, the titer of the obtained nipah pseudovirus is higher than that of the nipah pseudovirus packaged by an original sequence, and an unexpected technical effect is achieved. Besides, the Nipah pseudovirus has His, Myc and EGFP marks, the preparation effect of the pseudovirus can be visually observed, and the Nipah pseudovirus can be used for Nipah serological diagnosis, virus neutralizing antibody evaluation and the like and has a good application prospect.

The application discloses a kind of RNA virus nucleic acid preservative in fecal sample, including denaturant, chelating agent, pH buffering agent, osmotic pressure regulator and reducing agent;The denaturant includes guanidine salt and surfactant;The application further additionally provides a kind of RNA virus nucleic acid preservative in fecal sample preparation method, preparation above-mentioned one kind of RNA virus nucleic acid preservative in fecal sample, including the following steps: each component is mixed with ratio, pH is adjusted with pH buffering agent, with deionized water constant volume;Filter, obtain the preservative solution described in this application.The preservative solution of the application can stably store human cell DNA and viral RNA in fecal sample at room temperature for at least 7 days, which is beneficial for long-distance transportation at room temperature;Meanwhile, the preservative solution of the application also releases nucleic acid, inactivates virus, so as to prevent biological leakage and infection phenomenon;The de-inhibitor component in the preservative solution can directly combine and precipitate with various inhibitors in feces, reducing the interference to nucleic acid detection.